PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma (original) (raw)
Related papers
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
PLoS ONE, 2014
Abstract 2160: MEN1611, a novel α-selective PI3K inhibitor in solid tumors
Tumor Biology, 2018
A review on PIM kinases in tumors
Bioinformation, 2019
The α folate receptor is highly activated in malignant pleural mesothelioma
The Journal of Thoracic and Cardiovascular Surgery, 2001
Antitumor activity of MEK and PI3K inhibitors in malignant pleural mesothelioma
European Respiratory Journal, 2011
Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?
Journal of Cancer, 2016
Proceedings of the …, 2001
International journal of oncology, 2012
The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014
Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma
Carcinogenesis, 2002
2023
The eighth TNM classification for malignant pleural mesothelioma
Translational Lung Cancer Research, 2018
Anticancer …, 2006
Advances in malignant mesothelioma therapy: targeting EphA2 - a novel approach
Journal of Thoracic Oncology, 2009
Cancer Cell, 2015
Eighth International Mesothelioma Interest Group
Oncogene, 2007
Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells
PLoS ONE, 2012
2008
Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma
Cancer, 1997
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
British Journal of Cancer, 2014
Clinical aspects of malignant mesothelioma in Australia
Australian and New Zealand Journal of Medicine, 1993
Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal
Journal of Thoracic Oncology, 2018
Abstract A057: The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma
Cancer Stem Cells, 2019
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
ESMO Open
DNA copy number gains in malignant pleural mesothelioma
Oncology Letters, 2015
Therapies currently in Phase II trials for malignant pleural mesothelioma
Expert Opinion on Investigational Drugs, 2013
The Association Between Pleural Fluid Exposure and Survival in Pleural Mesothelioma
Chest, 2021
Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!
Pathology Research and Practice, 2022
Pleural mesothelioma incidence in Europe: Evidence of some deceleration in the increasing trends
Cancer Causes and Control, 2003
Metachronous malignant mesothelioma and pulmonary adenocarcinoma
Turkish Journal of Pathology, 2013
Anti-Cancer Drugs, 2000
BMC Cancer, 2014
ACS Medicinal Chemistry Letters, 2016
International Journal of Molecular Sciences